Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nilofer S Azad

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
International Journal of Cancer|February 5, 2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patientsValerie Lee, Rose Parkinson, Marianna Zahurak, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Journal of Clinical Investigation|September 17, 2019
Equity and diversity in academic medicine: a perspective from the JCI editorsLinda Ms Resar, Elizabeth M Jaffee, Mary Armanios, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The American Surgeon|May 9, 2025
Sustained Organ Preservation in Patients With Rectal Cancer After Sequential Short-Course Radiation Therapy and ChemotherapyI-Chia Liu, Susan Gearhart, Chen Hu, et al.
Cancer|December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trialsFen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Gastrointestinal Endoscopy|February 25, 2015
Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapyShalini Moningi, Amanda J Walker, Ashkan A Malayeri, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract CancerAmanda N Ruggieri, Mark Yarchoan, Subir Goyal, et al.
International Journal of Cancer|February 5, 2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patientsValerie Lee, Rose Parkinson, Marianna Zahurak, et al.
Investigational New Drugs|September 8, 2018
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The Journal of Clinical Investigation|September 17, 2019
Equity and diversity in academic medicine: a perspective from the JCI editorsLinda Ms Resar, Elizabeth M Jaffee, Mary Armanios, et al.
Investigational New Drugs|October 19, 2018
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancerLaura W Goff, Nilofer S Azad, Stacey Stein, et al.
The American Surgeon|May 9, 2025
Sustained Organ Preservation in Patients With Rectal Cancer After Sequential Short-Course Radiation Therapy and ChemotherapyI-Chia Liu, Susan Gearhart, Chen Hu, et al.
Cancer|December 19, 2025
Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trialsFen Saj, Felicity K Namayanja, Lianchun Xiao, et al.
Gastrointestinal Endoscopy|February 25, 2015
Analysis of fiducials implanted during EUS for patients with localized rectal cancer receiving high-dose rate endorectal brachytherapyShalini Moningi, Amanda J Walker, Ashkan A Malayeri, et al.
Pageof 11